Please assess the completion status of the following clinical trial:

Trial Title: VPD-737 for Treatment of Chronic Pruritus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chronic pruritus and unresponsive to current therapies~Exclusion Criteria:~* Have chronic liver or renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.25 mg VPD-737 (Type: EXPERIMENTAL): 0.25 mg of VPD-737 daily by mouth for 42 days
- 1 mg VPD-737 (Type: EXPERIMENTAL): 1 mg VPD-737 taken daily by mouth for 42 days
- 5 mg VPD-737 (Type: EXPERIMENTAL): 5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
- Placebo (Type: PLACEBO_COMPARATOR): placebo tablets to be taken daily by mouth for 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).